Satellos Bioscience (NASDAQ:MSLE) Downgraded by Zacks Research to “Strong Sell”

Satellos Bioscience (NASDAQ:MSLE) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Wednesday, Zacks reports.

A number of other analysts have also recently issued reports on MSLE. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Satellos Bioscience in a research report on Monday, August 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a research report on Friday, August 7th. Craig Hallum assumed coverage on shares of Satellos Bioscience in a report on Thursday, October 8th. They set a “buy” rating and a $24.00 price objective on the stock. Finally, Wells Fargo & Company set a $18.00 target price on Satellos Bioscience in a research note on Thursday, July 9th. Six analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.60.

Satellos Bioscience Price Performance

NASDAQ MSLE opened at $6.63 on Wednesday. Satellos Bioscience has a 12 month low of $5.30 and a 12 month high of $13.39. The company has a market capitalization of $140.69 million, a P/E ratio of -3.45 and a beta of 1.51. The company’s 50 day simple moving average is $8.66 and its 200 day simple moving average is $8.02.

Satellos Bioscience (NASDAQ:MSLE) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.18). On average, analysts anticipate that Satellos Bioscience will post -1.86 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Satellos Bioscience stock. AWM Investment Company Inc. increased its position in shares of Satellos Bioscience Inc. (NASDAQ:MSLE) by 41.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 305,000 shares of the company’s stock after acquiring an additional 90,000 shares during the quarter. AWM Investment Company Inc. owned about 1.46% of Satellos Bioscience worth $2,338,000 at the end of the most recent quarter.

Satellos Bioscience Company Profile

Satellos Bioscience Corporation (NASDAQ:MSLE) is a biotechnology company focused on developing therapies that promote the natural regeneration and repair of skeletal muscle. Its research is based on the role of muscle stem cells, also known as satellite cells, in maintaining and rebuilding muscle tissue after injury or disease.

The company’s lead program is SAT-3247, an investigational small-molecule therapy being developed for muscle-wasting disorders, including Duchenne muscular dystrophy.